Total Payments
$94,726
2024 Payments
$63,930
Companies
60
Transactions
432
Medicare Patients
1,890
Medicare Billing
$542,792
Payment Breakdown by Category
Other$57,130 (60.3%)
Consulting$15,679 (16.6%)
Travel$10,818 (11.4%)
Food & Beverage$10,736 (11.3%)
Education$363.33 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,130 | 23 | 60.3% |
| Consulting Fee | $15,679 | 6 | 16.6% |
| Travel and Lodging | $10,818 | 23 | 11.4% |
| Food and Beverage | $10,736 | 375 | 11.3% |
| Education | $363.33 | 5 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $31,359 | 63 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $18,373 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $16,376 | 30 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $13,882 | 13 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $6,044 | 5 | $0 (2024) |
| Genentech USA, Inc. | $1,434 | 10 | $0 (2024) |
| Incyte Corporation | $710.13 | 20 | $0 (2024) |
| Janssen Biotech, Inc. | $506.87 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $499.90 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $494.24 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,930 | 121 | Ipsen Biopharmaceuticals, Inc ($16,588) |
| 2023 | $25,208 | 85 | Astellas Pharma US Inc ($15,960) |
| 2022 | $800.27 | 28 | Boston Scientific Corporation ($145.18) |
| 2021 | $853.05 | 31 | Incyte Corporation ($193.35) |
| 2020 | $1,100 | 22 | Incyte Corporation ($223.03) |
| 2019 | $880.63 | 36 | Janssen Biotech, Inc. ($195.97) |
| 2018 | $600.97 | 40 | Astellas Pharma US Inc ($117.76) |
| 2017 | $1,353 | 69 | E.R. Squibb & Sons, L.L.C. ($289.73) |
All Payment Transactions
432 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,805.00 | General |
| Category: ONCOLOGY | ||||||
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,354.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Oncology | ||||||
| 12/13/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $120.61 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $7.12 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,570.00 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,515.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $624.98 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $809.86 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $157.06 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $122.63 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $33.12 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Oncology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.09 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $1,052.56 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,020.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 1,167 | 18,497 | $1.5M | $367,240 |
| 2022 | 27 | 723 | 13,058 | $781,076 | $175,552 |
Total Patients
1,890
Total Services
31,555
Medicare Billing
$542,792
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 6,000 | $815,200 | $258,090 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 368 | $135,424 | $34,242 | 25.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 12 | 14 | $67,228 | $16,546 | 24.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 104 | 112 | $79,184 | $11,532 | 14.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 80 | $28,560 | $7,436 | 26.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $26,233 | $6,127 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 30 | $14,880 | $3,812 | 25.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 63 | 350 | $22,400 | $3,605 | 16.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 20 | 20 | $21,340 | $3,258 | 15.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 73 | 129 | $20,253 | $2,875 | 14.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 60 | 277 | $5,540 | $2,319 | 41.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 63 | 306 | $11,016 | $2,316 | 21.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $10,410 | $2,047 | 19.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 26 | 93 | $9,207 | $1,696 | 18.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 29 | 30 | $9,390 | $1,436 | 15.3% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 25 | 25 | $20,525 | $1,264 | 6.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 24 | $8,256 | $1,237 | 15.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 63 | 90 | $9,720 | $1,087 | 11.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 11 | 12 | $7,884 | $1,082 | 13.7% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 11 | 12 | $6,000 | $970.08 | 16.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 13 | $2,743 | $699.71 | 25.5% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 25 | 4,200 | $21,000 | $553.08 | 2.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 68 | $29,308 | $450.17 | 1.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 34 | 370 | $42,180 | $322.74 | 0.8% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 11 | 15 | $1,710 | $286.30 | 16.7% |
About Dr. Benjamin Kitchens, MD
Dr. Benjamin Kitchens, MD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2013. The National Provider Identifier (NPI) number assigned to this provider is 1841637477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Kitchens, MD has received a total of $94,726 in payments from pharmaceutical and medical device companies, with $63,930 received in 2024. These payments were reported across 432 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($57,130).
As a Medicare-enrolled provider, Kitchens has provided services to 1,890 Medicare beneficiaries, totaling 31,555 services with total Medicare billing of $542,792. Data is available for 2 years (2022–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Student in an Organized Health Care Education/Training Program, Hematology & Oncology
- Location Dallas, TX
- Active Since 05/22/2013
- Last Updated 08/10/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841637477
Products in Payments
- Onivyde (Drug) $18,373
- FRUZAQLA (Drug) $13,870
- IMFINZI (Biological) $8,334
- ZIIHERA (Drug) $5,990
- Vyloy (Drug) $850.24
- ELIQUIS (Drug) $605.35
- IMBRUVICA (Drug) $436.74
- KEYTRUDA (Biological) $390.69
- CREON (Drug) $332.70
- XARELTO (Drug) $325.07
- MONJUVI (Drug) $316.98
- Lenvima (Drug) $241.52
- LIBTAYO (Biological) $221.56
- CRESEMBA (Drug) $212.84
- clonoSEQ (Device) $206.46
- ENTRESTO (Drug) $190.06
- ADCETRIS (Biological) $168.13
- BLENREP (Biological) $146.36
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $145.18
- Kcentra (Biological) $141.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262